Tissue vs. Fecal-Derived Bacterial Dysbiosis in Precancerous Colorectal Lesions: A Systematic Review.
bacteria
carcinoma in situ
colorectal adenoma
colorectal neoplasm
fecal-derived dysbiosis
gut
intestinal microbiota
mucosa samples
polyp
stool
tissue-derived
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
04 Mar 2023
04 Mar 2023
Historique:
received:
20
01
2023
revised:
19
02
2023
accepted:
02
03
2023
entrez:
11
3
2023
pubmed:
12
3
2023
medline:
12
3
2023
Statut:
epublish
Résumé
Alterations in gut microbiota play a pivotal role in the adenoma-carcinoma sequence. However, there is still a notable lack of the correct implementation of tissue and fecal sampling in the setting of human gut microbiota examination. This study aimed to review the literature and to consolidate the current evidence on the use of mucosa and a stool-based matrix investigating human gut microbiota changes in precancerous colorectal lesions. A systematic review of papers from 2012 until November 2022 published on the PubMed and Web of Science databases was conducted. The majority of the included studies have significantly associated gut microbial dysbiosis with premalignant polyps in the colorectum. Although methodological differences hampered the precise fecal and tissue-derived dysbiosis comparison, the analysis revealed several common characteristics in stool-based and fecal-derived gut microbiota structures in patients with colorectal polyps: simple or advanced adenomas, serrated lesions, and carcinomas in situ. The mucosal samples considered were more relevant for the evaluation of microbiota's pathophysiological involvement in CR carcinogenesis, while non-invasive stool sampling could be beneficial for early CRC detection strategies in the future. Further studies are required to identify and validate mucosa-associated and luminal colorectal microbial patterns and their role in CRC carcinogenesis, as well as in the clinical setting of human microbiota studies.
Identifiants
pubmed: 36900392
pii: cancers15051602
doi: 10.3390/cancers15051602
pmc: PMC10000868
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : Research Council of Lithuania (LMTLT)
ID : No. S-MIP-22-38
Références
Nat Commun. 2015 Mar 11;6:6528
pubmed: 25758642
Int J Cancer. 2017 Dec 15;141(12):2528-2536
pubmed: 28833079
J Gastroenterol. 2015 Feb;50(2):167-79
pubmed: 24811328
Am J Pathol. 2020 Jun;190(6):1309-1322
pubmed: 32194048
Clin Transl Gastroenterol. 2021 Aug 19;12(8):e00389
pubmed: 34408121
Med Sci Monit. 2017 Sep 14;23:4422-4430
pubmed: 28904330
Gastroenterology. 2021 Jun;160(7):2395-2408
pubmed: 33581124
Front Med (Lausanne). 2022 Jul 20;9:888340
pubmed: 35935780
Gut Microbes. 2022 Jan-Dec;14(1):2038863
pubmed: 35188868
Sci Rep. 2016 Apr 29;6:25271
pubmed: 27125587
Gut Microbes. 2010 May-Jun;1(3):138-47
pubmed: 20740058
Gut Microbes. 2021 Jan-Dec;13(1):1854641
pubmed: 33446008
J Cell Mol Med. 2021 Dec;25(23):10783-10797
pubmed: 34750964
J Gastroenterol Hepatol. 2020 Dec;35(12):2109-2121
pubmed: 32337748
Eur J Epidemiol. 2010 Sep;25(9):603-5
pubmed: 20652370
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Intest Res. 2018 Jul;16(3):346-357
pubmed: 30090033
Cancers (Basel). 2021 Dec 10;13(24):
pubmed: 34944836
PLoS One. 2016 May 12;11(5):e0155362
pubmed: 27171425
ISME J. 2012 Oct;6(10):1858-68
pubmed: 22622349
Nature. 2020 Apr;580(7802):269-273
pubmed: 32106218
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
BMC Cancer. 2019 Apr 29;19(1):399
pubmed: 31035942
Am J Clin Nutr. 2013 May;97(5):1044-52
pubmed: 23553152
World J Gastroenterol. 2020 Feb 14;26(6):614-626
pubmed: 32103871
Genes (Basel). 2020 Nov 20;11(11):
pubmed: 33233735
Neoplasma. 2018;65(4):644-648
pubmed: 29940777
Biomedicines. 2020 Nov 10;8(11):
pubmed: 33182693
Sci Rep. 2021 Feb 3;11(1):2925
pubmed: 33536501
Front Oncol. 2021 May 11;11:661048
pubmed: 34046355
Int J Mol Sci. 2021 Feb 01;22(3):
pubmed: 33535583
Proc Natl Acad Sci U S A. 2014 Dec 23;111(51):18321-6
pubmed: 25489084
Int J Cancer. 2016 Sep 15;139(6):1318-26
pubmed: 27130618
Microbiome. 2016 Dec 30;4(1):69
pubmed: 28038683
J Proteome Res. 2014 Apr 4;13(4):1921-9
pubmed: 24601673
Cochrane Database Syst Rev. 2019 Oct 3;10:ED000142
pubmed: 31643080
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2017 Dec;161(4):333-338
pubmed: 29235578
Dig Dis Sci. 2013 Jun;58(6):1717-26
pubmed: 23306850
Cancer Prev Res (Phila). 2014 Nov;7(11):1112-21
pubmed: 25104642
Cancers (Basel). 2020 May 02;12(5):
pubmed: 32370168
EBioMedicine. 2015 Apr 18;2(6):597-603
pubmed: 26288821
PLoS One. 2013;8(1):e53653
pubmed: 23335968
Sci Rep. 2016 May 19;6:26337
pubmed: 27194068
PLoS One. 2012;7(6):e39743
pubmed: 22761885
Gut. 2017 Apr;66(4):633-643
pubmed: 26992426
Cancer Epidemiol Biomarkers Prev. 2017 Jan;26(1):85-94
pubmed: 27672054
Oncotarget. 2015 Oct 13;6(31):32013-26
pubmed: 26397137
Clin Cancer Res. 2017 Apr 15;23(8):2061-2070
pubmed: 27697996
PLoS One. 2015 Mar 09;10(3):e0119462
pubmed: 25751261
PLoS One. 2013 Dec 20;8(12):e81352
pubmed: 24376500
Gut Pathog. 2014 Jun 25;6:26
pubmed: 24995042
Cancers (Basel). 2021 Jun 19;13(12):
pubmed: 34205378
mSystems. 2020 Apr 14;5(2):
pubmed: 32291348
Sci Rep. 2019 Jul 29;9(1):10923
pubmed: 31358825
Pathobiology. 2021;88(2):127-140
pubmed: 33291114
Microb Pathog. 2018 Nov;124:244-249
pubmed: 30142468
NPJ Biofilms Microbiomes. 2022 Aug 29;8(1):69
pubmed: 36038569
Mol Syst Biol. 2014 Nov 28;10:766
pubmed: 25432777
Cancer J. 2014 May-Jun;20(3):225-31
pubmed: 24855012
Ann Surg. 2023 Apr 1;277(4):e817-e824
pubmed: 35129506
Oncol Rep. 2016 Jan;35(1):325-33
pubmed: 26549775
Iran J Microbiol. 2019 Feb;11(1):1-6
pubmed: 30996824
Cancers (Basel). 2022 Sep 25;14(19):
pubmed: 36230584